Cargando…

BET inhibitor JQ1 enhances anti-tumor immunity and synergizes with PD-1 blockade in CRC

Most colorectal cancer (CRC) patients are insensitive to immune checkpoint inhibitors (ICIs) due to the immunosuppressive tumor microenvironment (TME). Epigenetic factors such as the bromo-and extraterminal domain (BET) family proteins may be responsible for the immunosuppressive microenvironment. P...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Huijin, Liu, Guangyao, Jin, Xinghan, Song, Shenglei, Chen, Songyao, Zhou, Peiqing, Li, Huan, Liang, Jianming, Li, Bo, Zhang, Changhua, He, Yulong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2022
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9066214/ https://www.ncbi.nlm.nih.gov/pubmed/35517410 http://dx.doi.org/10.7150/jca.69375

Ejemplares similares

Identification of a Two-Gene Signature and Establishment of a Prognostic Nomogram Predicting Overall Survival in Diffuse-Type Gastric Cancer
por: Chen, Songyao, et al.
Publicado: (2022)

BET bromodomain inhibitor (JQ1) and tumor angiogenesis
por: Bid, Hemant Kumar, et al.
Publicado: (2016)

Schlafen family is a prognostic biomarker and corresponds with immune infiltration in gastric cancer
por: Xu, Jiannan, et al.
Publicado: (2022)

The BET-bromodomain inhibitor JQ1 mitigates vemurafenib drug resistance in melanoma
por: Zhao, Bei, et al.
Publicado: (2018)

Modulation of Virulence-Associated Traits in Aspergillus fumigatus by BET Inhibitor JQ1
por: Orekhova, Anastasia, et al.
Publicado: (2022)

Isocitrate dehydrogenase 1 mutation sensitizes intrahepatic cholangiocarcinoma to the BET inhibitor JQ1
por: Fujiwara, Hiroaki, et al.
Publicado: (2018)

BET protein Brd4 activates transcription in neurons and BET inhibitor Jq1 blocks memory in mice
por: Korb, Erica, et al.
Publicado: (2015)

The BET/BRD inhibitor JQ1 improves brain plasticity in WT and APP mice
por: Benito, E, et al.
Publicado: (2017)

The BET Inhibitor JQ1 Potentiates the Anticlonogenic Effect of Radiation in Pancreatic Cancer Cells
por: Garcia, Patrick L., et al.
Publicado: (2022)

Sequential targeting of YAP1 and p21 enhances the elimination of senescent cells induced by the BET inhibitor JQ1
por: Zhang, Huan-Tian, et al.
Publicado: (2021)

BET-inhibition by JQ1 promotes proliferation and self-renewal capacity of hematopoietic stem cells
por: Wroblewski, Mark, et al.
Publicado: (2018)

Stromal remodeling by the BET bromodomain inhibitor JQ1 suppresses the progression of human pancreatic cancer
por: Yamamoto, Keisuke, et al.
Publicado: (2016)

The BET Inhibitor JQ1 Augments the Antitumor Efficacy of Gemcitabine in Preclinical Models of Pancreatic Cancer
por: Miller, Aubrey L., et al.
Publicado: (2021)

Akt/mTOR-Mediated Autophagy Confers Resistance To BET Inhibitor JQ1 In Ovarian Cancer
por: Luan, Wenqing, et al.
Publicado: (2019)

BET bromodomain inhibitor JQ1 regulates spermatid development by changing chromatin conformation in mouse spermatogenesis
por: Wang, Xiaorong, et al.
Publicado: (2021)

The BET Protein Inhibitor JQ1 Decreases Hypoxia and Improves the Therapeutic Benefit of Anti-PD-1 in a High-Risk Neuroblastoma Mouse Model
por: Sauvage, Delphine, et al.
Publicado: (2022)

BET protein inhibitor JQ1 inhibits growth and modulates WNT signaling in mesenchymal stem cells
por: Alghamdi, Saeed, et al.
Publicado: (2016)

The BET bromodomain inhibitor JQ1 activates HIV latency through antagonizing Brd4 inhibition of Tat-transactivation
por: Li, Zichong, et al.
Publicado: (2013)

Akt/mTOR-Mediated Autophagy Confers Resistance To BET Inhibitor JQ1 In Ovarian Cancer [Corrigendum]
Publicado: (2019)

BET Protein Inhibitor JQ1 Modulates Mitochondrial Dysfunction and Oxidative Stress Induced by Chronic Kidney Disease
por: Rayego-Mateos, Sandra, et al.
Publicado: (2023)

Image-based drug screen identifies HDAC inhibitors as novel Golgi disruptors synergizing with JQ1
por: Gendarme, Mathieu, et al.
Publicado: (2017)

BET protein inhibitor JQ1 downregulates chromatin accessibility and suppresses metastasis of gastric cancer via inactivating RUNX2/NID1 signaling
por: Zhou, Siqi, et al.
Publicado: (2020)

BET inhibitor JQ1 suppresses cell proliferation via inducing autophagy and activating LKB1/AMPK in bladder cancer cells
por: Li, Feng, et al.
Publicado: (2019)

JQ1 synergizes with the Bcl-2 inhibitor ABT-263 against MYCN-amplified small cell lung cancer
por: Wang, Huogang, et al.
Publicado: (2017)

Nanoparticles Loaded with the BET Inhibitor JQ1 Block the Growth of Triple Negative Breast Cancer Cells In Vitro and In Vivo
por: Maggisano, Valentina, et al.
Publicado: (2019)

Organoids From Mucinous Appendiceal Adenocarcinomas as High-Fidelity Models for Individual Therapy
por: Liu, Guangyao, et al.
Publicado: (2022)

Ethaselen synergizes with oxaliplatin in tumor growth inhibition by inducing ROS production and inhibiting TrxR1 activity in gastric cancer
por: Zhang, Haiyong, et al.
Publicado: (2021)

PD-1 Immune Checkpoint Blockade and PSGL-1 Inhibition Synergize to Reinvigorate Exhausted T Cells
por: Viramontes, Karla M., et al.
Publicado: (2022)

Hitting two oncogenic machineries in cancer cells: cooperative effects of the multi-kinase inhibitor ponatinib and the BET bromodomain blockers JQ1 or dBET1 on human carcinoma cells
por: Bauer, Karin, et al.
Publicado: (2018)

Bromodomains and Extra-Terminal (BET) Inhibitor JQ1 Suppresses Proliferation of Acute Lymphocytic Leukemia by Inhibiting c-Myc-Mediated Glycolysis
por: Zhang, Meng-Yi, et al.
Publicado: (2020)

SHP2 inhibition triggers anti-tumor immunity and synergizes with PD-1 blockade
por: Zhao, Mingxia, et al.
Publicado: (2019)

PD-1 blockade synergizes with oxaliplatin-based, but not cisplatin-based, chemotherapy of gastric cancer
por: Liu, Peng, et al.
Publicado: (2022)

Impact of Target Warhead and Linkage Vector on Inducing Protein Degradation: Comparison of Bromodomain and Extra-Terminal (BET) Degraders Derived from Triazolodiazepine (JQ1) and Tetrahydroquinoline (I-BET726) BET Inhibitor Scaffolds
por: Chan, Kwok-Ho, et al.
Publicado: (2017)

BET bromodomain inhibitor JQ1 preferentially suppresses EBV-positive nasopharyngeal carcinoma cells partially through repressing c-Myc
por: Li, Ning, et al.
Publicado: (2018)

GLI2-dependent c-MYC upregulation mediates resistance of pancreatic cancer cells to the BET bromodomain inhibitor JQ1
por: Kumar, Krishan, et al.
Publicado: (2015)

The BET inhibitor JQ1 attenuates double-strand break repair and sensitizes models of pancreatic ductal adenocarcinoma to PARP inhibitors
por: Miller, Aubrey L., et al.
Publicado: (2019)

Inhibition of Bromodomain and Extraterminal Domain (BET) Proteins by JQ1 Unravels a Novel Epigenetic Modulation to Control Lipid Homeostasis
por: Tonini, Claudia, et al.
Publicado: (2020)

BET Inhibitor JQ1 Attenuates Feline Leukemia Virus DNA, Provirus, and Antigen Production in Domestic Cat Cell Lines
por: Moll, Garrick M., et al.
Publicado: (2023)

Differential responses of pulmonary vascular cells from PAH patients and controls to TNFα and the effect of the BET inhibitor JQ1
por: Mumby, Sharon, et al.
Publicado: (2023)

The BET inhibitor JQ1 selectively impairs tumour response to hypoxia and downregulates CA9 and angiogenesis in triple negative breast cancer
por: da Motta, L L, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_k2g203mf69fsvmeucochi4ed1k